Abstract:Xiao-Min Liu 1 &ast, Wen-Ting Zhu 1 &ast, Meng-Lei Jia, 1 Yu-Ting Li, 1 Ye Hong, 1 Zhong-Qiu Liu, 2 Peng-Ke Yan 1 1 Department of Pharmacy, Biomedicine Research Center, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China; 2 Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhong-Qiu Liu, Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China, Email Peng-Ke Yan, Department of Pharmacy, Biomedicine Research Center, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China, Email Background: Transgenic C57BL/6-APC (Min/+) spontaneous cancer mouse model and the Azoxymethane (AOM)/Dextran Sulfate Sodium (DSS) chemically induced orthotopic colorectal cancer mouse model represented distinct pathogenesis of colorectal cancers. Our previous study revealed that the combination of Rapamycin liposomes (Rapa/Lps) and 5-Fluorouracil (5-FU) has anti-colorectal cancer effects. However, the therapeutic efficacy of Rapa/Lps and 5-FU in other colorectal cancer mice models is yet to be thoroughly explored. The purpose of this study was to investigate the anti-tumor effect of Rapa/Lps combined with 5-FU in vivo and in vitro. Methods: In this study, we evaluated the effect of Rapa/Lps and 5-FU on APC (Min/+) mice and AOM/DSS-induced colorectal cancer mice. The small intestine, colorectum, serum, and plasma of mice in each group were collected following sacrifice to record the number of tumors. HE staining was utilized for observing pathological damage to intestine tissues. Tube formation assay, Transwell assay, wound healing assay, Western Blot were used to explore the anti-angiogenesis effect of drugs in HUVECs. Results: As expected, Rapa/Lps and 5-FU significantly suppressed tumor formation, decreased the number of tumors, and tumor load both in two mouse models, and had no influence on mouse weight. Mechanically, the anti-tumor effect of the drug also was associated in inhibiting angiogenesis and proliferation. Furthermore, we found that Rapa/Lps obviously inhibited HUVECs tube formation and migration. Conclusion: Altogether, we revealed the Rapa/Lps synergism with 5-FU decreased colon and small intestinal tumorigenesis in AOM/DSS-treated and APC (Min/+) mice, respectively, and correlated with anti-angiogenesis. Keywords: rapamycin liposomes, 5-fluorouracil, angiogenesis, APC (Min/+) mice, AOM/DSS, colorectal cancer Colorectal Cancer (CRC) is the third leading cause of cancer death in both men and women. 1 Accumulating studies show that inflammatory factors, immune cells, genetic factors, and intestinal flora contribute to the occurrence, development, and metastasis of CRC. 2 APC (Min/+) mice can spontaneously generate a large number of intestinal multiple adenomas, which is an excellent animal model for familial adenomatous polyposis (FAP) research. 3 The combination of azoxymethane (AOM) and dextran sodium sulfate (DSS) can induce colitis-associated cancer mice model. 4 The clinical treatment of colorectal cancer includes surgery, chemotherapy, and radiotherapy. 5 5-Fluorouracil (5-FU) was the first-line basic chemotherapy agent for colorectal cancer, but it also has disadvantages such as high toxic side effects and has easy drug resistance. 6 The combination of different drugs is routinely used in clinical practice for the treatment of cancer. It not only reduces the dosage of single drugs and provides a synergistic effect, but also may improve the toxic side effects of the drugs. 7 For example, ethanolic extracts of Thai noni juice (TNJ) products in combination with 5-FU enhanced the anti-cholangiocarcinoma activity in mouse KKU-100 xenograft model through apoptosis induction and reduced toxicity of 5-FU. 8 In another study, metformin synergized with 5-FU to inhibit CRC proliferation and metastasis. 9 Rapamycin, a classic mTOR inhibitor, has recently been approved as an anti-cancer therapy in a variety of preclinical models for the treatment of renal cell carcinoma, pancreatic cance -Abstract Truncated-

Combined Inhibition of Dnmt and Mtor Signaling Inhibits Formation and Growth of Colorectal Cancer

Combined Inhibition of Mek and Mtor Signaling Inhibits Initiation and Progression of Colorectal Cancer

DNA Methyltransferase Inhibitor and Rapamycin Synergistically Modulate Cell Cycle and Mammalian Target of Rapamycin Signaling Pathway for Human Colorectal Cancer Cells

Inhibition of colon cancer in mouse of rapamycin combined with 5-aza-dC and its mechanisms

Rapamycin and PD98059 Collaborative Inhibit Mammalian Target of Rapamycin Pathway in the Prevention and Treatment of Mouse Colorectal Cancer

[Synergistic Effect of Rapamycin (RPM) and PD98059 on Cell Cycle and Mtor Signal Transduction in Human Colorectal Cancer Cells].

[RAD001 Reverses Radio-Resistance and Exerts Synergistic Tumor Inhibition with 5-Fluorouracil].

Mammalian Target of Rapamycin Pathway Inhibition Enhances the Effects of 5-Aza-dc on Suppressing Cell Proliferation in Human Gastric Cancer Cell Lines

Significance of Mtor Signaling and Its Inhibitor Against Cancer Stem-Like Cells in Colorectal Cancer

Targeted Inhibition of Mammalian Target of Rapamycin (mtor) Enhances Radiosensitivity in Pancreatic Carcinoma Cells.

Mtor Signaling Pathway is a Target for the Treatment of Colorectal Cancer

Dichloroacetic acid and rapamycin synergistically inhibit tumor progression

Anti-Cancer Effects of Zotarolimus Combined with 5-Fluorouracil Treatment in HCT-116 Colorectal Cancer-Bearing BALB/c Nude Mice

Rapamycin Liposomes Combined with 5-Fluorouracil Inhibits Angiogenesis and Tumor Growth of APC (Min/+) Mice and AOM/DSS-Induced Colorectal Cancer Mice

The Effect of Mtor Inhibition Alone or Combined with MEK Inhibitors on Brain Metastasis: an in Vivo Analysis in Triple-Negative Breast Cancer Models

Rapamycin circumvents anti PD-1 therapy resistance in colorectal cancer by reducing PD-L1 expression and optimizing the tumor microenvironment

Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.

Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma

Combination of Rapamycin and Garlic-Derived S-allylmercaptocysteine Induces Colon Cancer Cell Apoptosis and Suppresses Tumor Growth in Xenograft Nude Mice Through Autophagy/p62/nrf2 Pathway.

Data from Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells

Rapamycin And Trametinib: A Rational Combination For Treatment Of Nsclc